CAP-Ketamine for Antidepressant Resistant PTSD

Dose-related effects of ketamine for antidepressant-resistant symptoms of posttraumatic stress disorder in veterans and active duty military: a double-blind, randomized, placebo-controlled multi-center clinical trial

This double-blind RCT (n=158) assessed 8 repeated doses of intravenous ketamine administered twice weekly at a low dose (0.2 mg/kg; n = 53), standard dose (0.5 mg/kg; n = 51) ketamine or placebo (n=54) in veterans and service members with PTSD. It was found that the standard dose of ketamine reduced MADRS scores significantly more than placebo. However, the trial failed to find a significant dose-related effect of ketamine on PTSD symptoms measured using the CAPS-5.

Published

January 19, 2022

Journal

Neuropsychopharmacology

Authors

Abdallah, C. G., Roache, J. D., Gueorguieva, R., Averill, L. A., Young-McCaughan, S., Shiroma, P. R., Purohit, P., Brundige, A., Murff, W., Ahn, K-H., Baltutis, E. J., Ranganathan, M., D’Souza, D. C., Souza, S. E., Martini, B., Southwick, S. M., Burson, R. R., Guthmiller, K. B., McCallin, J. P., Hoch, M. B., Timchenko, A., Bryant, C. E., Mintz, J., Williamson, D. E., Keane, T. M., Peterson, A. L., Krystal, J. H.